Your browser doesn't support javascript.
loading
Concurrent Denosumab and Parenteral Iron Therapy Precipitating Severe Hypocalcemia and Hypophosphatemia.
Ye, Sylvia; Grill, Vivian; Luo, Jinghang; Nguyen, Hanh H.
Afiliación
  • Ye S; Endocrinology and Diabetes Unit, Western Health, Melbourne, VIC 3021, Australia.
  • Grill V; Endocrinology and Diabetes Unit, Western Health, Melbourne, VIC 3021, Australia.
  • Luo J; Department of Medicine, The University of Melbourne, Melbourne, VIC 3021, Australia.
  • Nguyen HH; Endocrinology and Diabetes Unit, Western Health, Melbourne, VIC 3021, Australia.
JCEM Case Rep ; 2(2): luae005, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38304007
ABSTRACT
Denosumab-induced hypocalcemia and iron infusion-related hypophosphatemia are both well described. We describe a case of severe hypocalcemia and hypophosphatemia following sequential denosumab and parenteral iron administration. This resulted in respiratory failure due to muscle weakness and cardiac arrhythmia, requiring noninvasive ventilation and urgent intravenous electrolyte replacement. This case highlights the severe dysregulation in calcium and phosphate homeostasis that can occur with denosumab and iron infusions when administered in quick succession. Given that these drugs are among the most common therapies prescribed across a range of specialties, we hope to alert clinicians to this potential serious drug-drug interaction and suggest strategies for monitoring and management of the electrolyte derangement.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JCEM Case Rep Año: 2024 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JCEM Case Rep Año: 2024 Tipo del documento: Article País de afiliación: Australia
...